Levcycloserine

Levcycloserine

SCHEMBL243772

N[C@H]1CONC1=O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

alrddl

The experimentally established mechanism targets of Levcycloserine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cycloserine SCHEMBL34322 1.00
Cycloserine SCHEMBL8681117 1.00 BLM (1.00)
Cycloserine SCHEMBL8681114 1.00 BLM (1.00)
Cycloserine SCHEMBL34323 1.00
Cycloserine SCHEMBL18584681 1.00 BLM (1.00)
Cycloserine SCHEMBL6571320 0.97
Cycloserine SCHEMBL429258 0.97
Cycloserine SCHEMBL10448776 0.97
Cycloserine SCHEMBL5351530 0.89 BLM (0.79)
Cycloserine SCHEMBL3921591 0.89 BLM (0.79)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2889 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719059-A1 INCREASED PALATABILITY OF INSECTICIDAL INSECT BAITS Bio Logic Crop Science, S.L. (ES) 2026-04-08 EP claimed
EP-4702978-A1 AGENT FOR TREATING OR PREVENTING AMYOTROPHIC LATERAL SCLEROSIS Socium Inc. (JP) 2026-03-04 EP claimed
WO-2026041700-A1 PROCESS FOR PREPARING OXAZOLE COMPOUNDS BASF SE (DE) 2026-02-26 WO claimed
US-20260027140-A1 COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA ATOPIC MEDICAL INC (US) 2026-01-29 US claimed
US-20250367153-A1 COMPOSITION AND APPLICATION THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2025-12-04 US claimed
EP-4583860-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-16 EP claimed
US-20250222117-A1 COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE PURDUE RESEARCH FOUNDATION 2025-07-10 US claimed
CN-115944627-B Pharmaceutical composition for treating breast cancer 山西医科大学 2025-03-14 CN claimed
CN-111526873-B For modulating microbial colonization substituted diphenylacetylenes of (2) 生物曼迪克斯有限责任公司 2025-03-04 CN claimed
CN-119212703-A Therapeutic or prophylactic agent for amyotrophic lateral sclerosis 寿协株式会社 2024-12-27 CN claimed
US-6190894-B1 APPLYING INHIBITORS OF BIOSYNTHESIS OR DEGRADATION, DEGRADATION ENZYMES, AND/OR INHIBITORS AND ACTIVATORS OF METABOLIC ENZYMES; FOR TOPICAL ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE SUBSTANCES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-02-20 US claimed
CN-1264430-A Betaines as adjuvants to susceptibility testing and antimicrobial therapy INTEGRATED RES TECHNOLOGY PLC (US) 2000-08-23 CN claimed
CN-1248923-A Device and method for delivery of drugs and genes using electroporation route GENETRONICS INC (US) 2000-03-29 CN claimed
WO-1998017253-A1 METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-04-30 WO claimed
EP-0764017-A4 METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION CELLEGY PHARMA INC (US) 1997-08-06 EP claimed
EP-0764017-A1 METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION CELLEGY PHARMACEUTICALS, INC. (US) 1997-03-26 EP claimed
WO-1996030381-A1 IMMUNOSUPPRESSIVE AGENTS NOVO NORDISK A/S (DK) 1996-10-03 WO claimed
WO-1996013263-A2 METHODS OF TREATMENT OF VIRAL DISEASE WITH INHIBITORS OF SPHINGOLIPID BIOSYNTHESIS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1996-05-09 WO claimed
WO-1994021230-A1 METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION CELLEGY PHARMACEUTICALS, INC. (US) 1994-09-29 WO claimed
US-5302609-A Administering synthetase inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1994-04-12 US claimed